Now in its 4e, "Osteoporosis" is a classic reference on this disease, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume work is a must-have for academic and medical libraries, physicians, researchers, and any company involved in osteoporosis research and development. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in which direct care costs for osteoporotic fractures in the United States reach up to $18 billion each year. Worldwide, 200 million women ages 60 to 80 suffer from osteoporosis and have a lifetime risk of fracture between 30% and 40%, continuing to make osteoporosis a critical challenge in medicine.
Recognizes the critical importance of the Wnt signaling pathway for bone health Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone Examines essential updates on estrogen prevention and treatment and the recent results from the WHODiscusses the controversial topics of screening and clinical trial design for drug registration Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics
Now in its 4e, "Osteoporosis" is a classic reference on this disease, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume work is a must-have for academic and medical libraries, physicians, researchers, and any company involved in osteoporosis research and development. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in which direct care costs for osteoporotic fractures in the United States reach up to $18 billion each year. Worldwide, 200 million women ages 60 to 80 suffer from osteoporosis and have a lifetime risk of fracture between 30% and 40%, continuing to make osteoporosis a critical challenge in medicine.
Recognizes the critical importance of the Wnt signaling pathway for bone health Incorporates new chapters on osteocytes, phosphatonins, mouse genetics, and CNS and bone Examines essential updates on estrogen prevention and treatment and the recent results from the WHODiscusses the controversial topics of screening and clinical trial design for drug registration Includes essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, and parathyroid hormone Offers critical reviews of reproductive and hormonal risk factors, ethnicity, nutrition, therapeutics, management, and economics